title: Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
abstract: The study examined the relationship between continued non-medical drug use and treatment retention for patients receiving buprenorphine maintenance treatment in a comprehensive addiction treatment program. The participants were 106 newly admitted patients and 103 continuing patients in treatment for an average of 9.4 months at the start of the study. Retrospective chart reviews were used to determine for each group whether the use of illicit, non-prescribed drugs during a 3-month baseline period was associated with lowered rates of treatment retention over the following 14 months. The New Admissions group was divided into 4 subgroups based on the percentage of urine drug tests that were positive during baseline: 0, 1-33, 34-67, or 68-100%. Because only 16 (15%) of the continuing patients had positive drug tests during baseline, the continuing group was divided into just 2 subgroups-no positives and any positives. Newly admitted patients testing positive for drugs more than 33% of the time were significantly more likely than those with less frequent or no positive tests to withdraw from treatment within 2 months. Continuing patients with at least 1 positive drug test left treatment 6 months sooner, on average, than those with no positive tests and were twice as likely to leave without completing continuing care (87 to 42%). Non-prescribed drug use during buprenorphine maintenance treatment is strongly correlated with lowered retention and risk of early treatment termination for new and continuing patients. Actions taken to monitor and reduce drug use during buprenorphine maintenance treatment may improve retention and enhance long-term recovery outcomes.
authors.affiliation: a Institute for Behavior and Health, Inc. , Rockville , Maryland , USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Campbell
authors.affiliation: b Kolmac Clinic , Burtonsville , Maryland , USA.
authors.forename: George
authors.initials: G
authors.lastname: Kolodner
authors.affiliation: a Institute for Behavior and Health, Inc. , Rockville , Maryland , USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Spencer
authors.affiliation: a Institute for Behavior and Health, Inc. , Rockville , Maryland , USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: DuPont
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000706:statistics & numerical data; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment / Q000379:methods / Q000706:statistics & numerical data; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000453:epidemiology; D010349:Patient Compliance / Q000706:statistics & numerical data*; D015813:Substance Abuse Detection / Q000706:statistics & numerical data*; D016320:Substance Abuse Treatment Centers / Q000706:statistics & numerical data; D013997:Time Factors; D055815:Young Adult
chemical_list: D009292:Narcotic Antagonists; D002047:Buprenorphine
keywords: Buprenorphine; drug addiction; opiate addiction; opiate substitution treatment; opioid substitution therapy; opioid-related disorders